Impaired IL-6 signaling has been detected in peripheral T cells from both non-small cell lung cancer (NSCLC) patients with high vs low plasma IL-6 concentrations, and in breast cancer patients compared to healthy donors. This evidence concerns the gene IL6 and non-small cell lung carcinoma.